购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • Glucokinase
    (1)
  • Others
    (3)
TargetMol | Tags 通过 货期 筛选
  • 5日内发货
    (4)
  • 20日内发货
    (2)
  • 6-8周
    (2)
  • 8-10周
    (1)
抑制剂&激动剂
细分筛选
搜索结果
TargetMol产品目录中 "glucokinase in human"的结果
筛选
搜索结果
TargetMol产品目录中 "

glucokinase in human

"的结果
  • 抑制剂&激动剂
    4
    TargetMol | Inhibitors_Agonists
  • 重组蛋白
    3
    TargetMol | Recombinant_Protein
  • 检测抗体
    2
    TargetMol | Antibody_Products
  • PF-04991532
    T164801215197-37-7
    PF-04991532 is an effective, hepatoselective glucokinase activator. It has EC50s of 80 and 100 nM in human and rat, respectively.
    • ¥ 534
    5日内发货
    规格
    数量
  • GKA-22
    GKA22,GKA 22
    T25451480463-02-3
    GKA-22 is a human glucokinase allosteric activator in the absence of glucose.
    • ¥ 11700
    6-8周
    规格
    数量
  • GKA50 quarterhydrate
    T63019
    GKA50 quarterhydrate 是一种有效的葡萄糖激酶激活剂,其 EC50 值为 33 nM。GKA50 quarterhydrate 是一种啮齿动物和人类胰岛中 β 细胞代谢的葡萄糖样激活剂,也是一种 Ca2+依赖性胰岛素分泌调节剂。GKA50 quarterhydrate 能够刺激小鼠胰岛分泌胰岛素,可以显著降低高脂喂养的雌性大鼠血糖。
    • ¥ 11131
    10-14周
    规格
    数量
  • AMG151 HCl
    T703911609674-80-7
    ARRY-403, also known as AMG-151, is an orally available allosteric glucokinase (GK) activator developed for the treatment of type 2 diabetes mellitus (T2DM). ARRY-403 has many favorable physicochemical characteristics and ADME properties (low potential to cause drug–drug interactions (DDIs). ARRY-403 potently activates human glucokinase (GK) in vitro (EC50 = 79 nM at 5 mM glucose), with an S0.5 = 0.93 mM glucose (ARRY-403 at 5 mM) and Vmax = 134% compared to the no activator control. It possesses good in vitro drug-like properties (aqueous solubility, cell permeability, low low potential for drug-drug interactions, low predicted hepatic clearance), and selectivity against broad panels of receptors and enzymes.
    • ¥ 15000
    8-10周
    规格
    数量